Amy Hankin

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Fatima Karzai, David James VanderWeele, Ravi A. Madan et al. · Journal for ImmunoTherapy of Cancer · 2018 · 312 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer

Michael J. Pishvaian, Rebecca Slack, Wei Jiang et al. · Cancer · 2018 · 68 citations · Full text

Medicine, Oncology, Pharmacology +16

A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population.

Fatima Karzai, Ravi A. Madan, Helen Owens et al. · Journal of Clinical Oncology · 2018 · 49 citations

Medicine, Oncology, Pharmacology +17

Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response

Fatima Karzai, Stephanie M. Walker, Scott Wilkinson et al. · Clinical Cancer Research · 2020 · 38 citations · Full text

Medicine, Oncology, Radiology +17

Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer

Ravi A. Madan, Fatima Karzai, Renee N. Donahue et al. · Journal for ImmunoTherapy of Cancer · 2021 · 30 citations · Full text

Medicine, Oncology, Pharmacotherapy +17